Endogenous IFNβ expression predicts outcome in critical patients with COVID-19

Menezes, Soraya Maria; Braz, Marcos; Lloréns‐Rico, Verónica; Wauters, Joost; Weyenbergh, Johan Van

doi:10.1016/s2666-5247(21)00063-x

Cited by 10 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, Menezes et al investigated the interferon, I, II, and III gene expression at the nasal mucosa of COVID-infected patients. These authors found that higher levels of the IFNB1 transcript predicted poor outcomes (91). However, children with COVID-19 present higher levels of IFN-a in nasal fluid than adults and present less severe symptoms, indicating a good outcome (92).…”

Section: Discussionmentioning

confidence: 99%

Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

IntroductionCoronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, resulting in a range of clinical manifestations and outcomes. Laboratory and immunological alterations have been considered as potential markers of disease severity and clinical evolution. Type I interferons (IFN-I), mainly represented by IFN-α and β, are a group of cytokines with an important function in antiviral responses and have played a complex role in COVID-19. Some studies have demonstrated that IFN-I levels and interferon response is elevated in mild cases, while other studies have noted this in severe cases. The involvement of IFN-I on the pathogenesis and outcomes of SARS-CoV-2 infection remains unclear. In this study, we summarize the available evidence of the association of plasma protein levels of type I IFN with the severity of COVID-19.MethodsThe PRISMA checklist guided the reporting of the data. A systematic search of the MEDLINE (PubMed), EMBASE, and Web of Science databases was performed up to March of 2021, looking for articles that evaluated plasma protein levels of IFN-I in mild, severe, or critical COVID-19 patients. Comparative meta-analyses with random effects were performed to compare the standardized mean differences in plasma protein levels of IFN-I of mild versus severe and mild versus critical patients. Meta-regressions were performed to test the moderating role of age, sex, time that the IFN-I was measured, and limit of detection of the assay used in the difference between the means.ResultsThere was no significant difference in plasma levels of IFN-α when comparing between mild and severe patients (SMD = -0.236, 95% CI -0.645 to 0.173, p = 0.258, I2 = 82.11), nor when comparing between patients mild and critical (SMD = 0.203, 95% CI -0.363 to 0.770, p = 0.481, I2 = 64.06). However, there was a significant difference between healthy individuals and patients with mild disease (SMD = 0.447, 95% CI 0.085 to 0.810, p = 0.016, I2 = 62.89).ConclusionsPeripheral IFN-α cannot be used as a severity marker as it does not determine the clinical status presented by COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…RNA was extracted from nasopharyngeal swabs as described above and used for hybridization to pre-speci ed Human Immunology V2 and customized SARS-CoV-2 panels, as described elsewhere. [22][23][24] Analysis of publicly available bulk and single-cell RNAseq data Bulk RNAseq data from both nasopharyngeal and blood samples, as well as corresponding gene signatures of fatal vs. non-fatal COVID-19 in hospitalized patients were obtained from Lee et al 25 Singlecell RNA-Seq data 26 of nasopharyngeal samples of 19 COVID-19 patients (8 moderate and 11 critical according to WHO classi cation) and ve healthy controls were obtained from https://doi.org/10.6084/m9. gshare.12436517, single-cell RNAseq data from PBMCs of COVID-19 patients were obtained from www.covidcellatlas.com 27 .…”

Section: Immunovirological Pro Ling By Digital Transcriptomics (Ncoun...mentioning

confidence: 99%

“…In search of candidate biomarkers for post-vaccine fatal COVID-19, as well as possible novel therapeutic targets, we opted for nCounter digital transcriptomics for immunovirological pro ling of the nasal mucosa, encouraged by previous results [22][23][24] . For 20 out of 28 fatal cases, a su cient volume of diagnostic nasopharyngeal swabs was available for nCounter analysis, to explore immunological (600 genes representative of the major immune cell types) and virological parameters (SARS-CoV-2 transcripts and ACE2/TMPRSS2 receptors) as possible risk factors for fatal post-vaccine COVID-19.…”

Section: Virological and Immunological Characterization Of Sars-cov-2...mentioning

confidence: 99%

Comprehensive immunovirological and environmental screening reveals risk factors for fatal COVID-19 during post-vaccination nursing home outbreaks

Cuypers

Keyaerts

Hong

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

COVID-19 vaccination has resulted in excellent protection against fatal disease, including in the elderly. However, risk factors for post-vaccination fatal COVID-19 are largely unknown. We comprehensively studied three large nursing home outbreaks (20-35% fatal cases) by combining SARS-CoV-2 aerosol monitoring, whole-genome phylogenetic analysis, and immunovirological profiling by digital nCounter transcriptomics. Phylogenetic investigations indicated each outbreak stemmed from a single introduction event, though with different variants (Delta, Gamma, and Mu). SARS-CoV-2 was detected in aerosol samples up to 52 days after the initial infection. Combining demographic, immune and viral parameters, the best predictive models for mortality comprised IFNB1 or age, viral ORF7a and ACE2 receptor transcripts. Comparison with published pre-vaccine fatal COVID-19 signatures and reanalysis of single-cell RNAseq data highlights the unique immune signature in post-vaccine fatal COVID-19 outbreaks. A multi-layered strategy including environmental sampling, immunomonitoring, and early antiviral therapy should be considered to prevent post-vaccination COVID-19 mortality in nursing homes.

show abstract

“…On the other hand, the patients recruited in the nebulized therapy are less severe than the patients in the SOLIDARITY trial. Furthermore, in a transcriptomic analysis IFN β expression in the nasal mucosa, independent of viral road, predicted the clinical outcome of severe COVID-19 patients [ 94 ]. Of note, the INF β has a detrimental effect in the severe stages of COVID-19.…”

Section: Clinical Interventionsmentioning

confidence: 99%

Interferon β, an enhancer of the innate immune response against SARS-CoV-2 infection

Kali

Dröge

Murugan

2021

Microbial Pathogenesis

View full text Add to dashboard Cite

COVID-19 exhibits a global health threat among the elderly and the population with underlying health conditions. During infection, the host's innate immune response acts as a frontline of defense by releasing cytokines such as type I interferon (IFN α and β) thereby initiating antiviral activity. However, this particular interferon response is interrupted by factors such as SARS-CoV-2 non-structural proteins, aging, diabetes, and germ-line errors eventually making the host more susceptible to illness. Therefore, enhancing the host's innate immune response by administering type I IFN could be an effective treatment against COVID-19. Here, we highlight the importance of innate immune response and the role of IFN β monotherapy against COVID-19.

show abstract

Endogenous IFNβ expression predicts outcome in critical patients with COVID-19

Cited by 10 publications

References 5 publications

Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis

Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis

Comprehensive immunovirological and environmental screening reveals risk factors for fatal COVID-19 during post-vaccination nursing home outbreaks

Interferon β, an enhancer of the innate immune response against SARS-CoV-2 infection

Contact Info

Product

Resources

About